



Press release

Dr. Bert S.J. van Toor joins the investment team of Global Life Science Ventures

Zug/Munich/London, 17 June 2004 – *Global Life Science Ventures (GLSV)* today announced that Dr. Bert S.J. van Toor has been appointed as Investment Manager. This appointment continues the planned expansion of the company's investment team in Europe to accommodate GLSV's increased geographic presence in Germany, Switzerland as well as the United Kingdom. As a member of the GLSV investment team, Dr. van Toor will operate from the company's Zug office in Switzerland. He will be actively involved in evaluating potential investments, developing GLSV's portfolio of companies in the life sciences, and providing further counselling for the management of the fund.

Peter Reinisch, PhD, Partner of Global Life Science Ventures, commented: "We are extremely pleased to welcome Dr. van Toor as the latest member of the team. Bert has over 10 years of experience in senior level positions in the drug discovery and development industry. His background in a range of therapeutic areas includes global responsibilities in pharmaceutical development at leading big pharma companies." He added: "His medical expertise as well as his strong industry background will be extremely useful to GLSV as we pursue the development of our investment portfolio."

Dr. van Toor qualified as a medical doctor at the University of Amsterdam in 1988 and obtained accreditation as a clinical pharmacologist in Mainz, Germany. From 1988-1991, he was a resident at two university hospitals in his home country, The Netherlands. From 1992-2001, Dr. van Toor held positions of increasing responsibility at Boehringer Ingelheim in Germany in clinical pharmacology and global clinical research. From 2001 onwards, Dr. van Toor worked at Bayer AG in several positions including global project management, clinical development and as interim medical director of the Benelux region (Belgium, The Netherlands, and Luxembourg). He was also involved in the evaluation of many in- and out-licensing opportunities, reviewing and optimizing R&D processes, as well as providing guidance on diverse research and development projects in respiratory disease and urology.

Dr. van Toor speaks Dutch, English, German and French fluently.

About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 29 leading biotechnology companies, five of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



Global Life Science Ventures – one team – three locations – global perspective

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30
www.glsv-vc.com
mailbox@glsv-vc.com

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

UK

GLSV Ltd.
1, Northumberland Avenue
London WC2N 5BW, UK
Tel. +44 (0)20 89 38 66 92
Fax +44 (0)20 89 38 77 40

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch